.png)
Highlights & Summary
Pharma-AI partnerships led October, with AstraZeneca committing $40M upfront and up to ~$1.46B in milestones to insitro for MASH and cardiomyopathy targets, and Bristol Myers Squibb leading Pathos AI's $237M Series E alongside a $55M neurology data deal with Tempus. In diagnostics, NeoGenomics moved its digital pathology onto a cloud, AI-ready platform with Indica Labs, while Cent acquired an AI radiology reporting startup. Health systems continued to embed AI directly into clinical workflows, with NYU Langone integrating OpenEvidence into Epic and Sentara deploying an AI case management tool.
Dexter: Is your team looking to speak with stakeholders, decision makers, or other KOLs? Dexter Experts is a self-service platform that lets you quickly & price effectively schedule 1-on-1 interviews or surveys. Reach out to the team for more info here.
Headlines
AI in Drug Discovery
1 | insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies | Partnership
3 | Metis TechBio Entered Strategic Collaboration with Lilly to Advance Next-Generation Tissue-Specific LNP Delivery Technologies | Partnership
AI in Diagnostics
1 | NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology | Partnership
2 | Cent Raises $15M Series A and Acquires AI Radiology Platform Medsee | M&A
3 | Microsoft Develops AI Tool That Can Diagnose 'Sequentially' Like a Doctor | New Product
AI in Healthcare
1 | OpenEvidence and NYU Langone Health Partner to Bring Patient-Aware Intelligence to 12 Million Visits in New York City | Partnership
2 | Vitalize Raises $31M Series A to Bring "Air Traffic Control" to Healthcare | Financing
3 | Sentara Health Deploys New AI Case Management Tool Co-Developed with Regard | New Product
Summaries
AI in Drug Discovery
1 | insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies | Partnership
insitro and AstraZeneca signed an exclusive research collaboration to discover novel targets and therapeutics in metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. insitro will receive $40M upfront with ~$1.46B in potential milestones to apply its Virtual Human causal AI platform to identify disease drivers and advance AstraZeneca-nominated targets through to development candidate, while AstraZeneca leads clinical development, regulatory work, and commercialization.
Pathos will license a de-identified, longitudinal dataset spanning hundreds of thousands of neurology patients from Tempus under a five-year, $55M agreement and analyze it using its Foundry agentic AI platform to generate disease biology hypotheses and inform adaptive trial designs. Pathos also secured BMS as the lead investor in its $237M Series E (~$3B post-money valuation), granting BMS non-exclusive Foundry access across its portfolio and three-year exclusive rights in neuroscience, extending Pathos’s oncology-focused approach into neurology.
3 | Metis TechBio Entered Strategic Collaboration with Lilly to Advance Next-Generation Tissue-Specific LNP Delivery Technologies | Partnership
Metis TechBio will apply its AI-driven ionizable lipid discovery and optimization platform, AiLNP, to design lipid nanoparticles with improved tissue targeting and biodistribution, with Lilly contributing drug discovery, development, and commercialization expertise. Metis is eligible for a low double-digit-million USD upfront payment, up to ~$1.1B in development, regulatory, and commercial milestones, and single-digit tiered royalties.
AI in Diagnostics
1 | NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology | Partnership
NeoGenomics selected Indica Labs' HALO AP platform to run its digital pathology operations on a scalable, cloud-based, vendor-neutral framework that can incorporate third-party or in-house AI tools while limiting integration costs. The company positions the infrastructure to support AI-based biomarker applications as the antibody-drug conjugate pipeline grows, as well as future AI co-development and clinical trial collaborations and larger curated pathology datasets.
2 | Cent Raises $15M Series A and Acquires AI Radiology Platform Medsee | M&A
Preventive health startup Cent raised a $15M Series A led by Blume Ventures with South Park Commons, reportedly a mix of debt and equity, and acquired Medsee, an AI radiology reporting platform.
3 | Microsoft Develops AI Tool That Can Diagnose 'Sequentially' Like a Doctor | New Research
Microsoft has developed an AI tool which coordinates and sequences patient questions as well as exams and tests to provide clinical diagnoses. Researchers at the company say their tool is more than twice as accurate as general physicians, and have published details of their work in Science. Unlike other models which often attempt to make a call based on a patient's whole clinical picture, Microsoft's tool instead attempts to build a working hypothesis which it refines through sequential questions and test ordering.
AI in Healthcare
1 | OpenEvidence and NYU Langone Health Partner to Bring Patient-Aware Intelligence to 12 Million Visits in New York City | Partnership
NYU Langone will embed OpenEvidence directly into its Epic EHR, letting clinicians ask complex clinical questions in natural language and receive answers grounded in peer-reviewed literature with patient context, without leaving the Epic workflow. The system handles roughly 12.4M outpatient visits a year, making this one of the largest EHR-embedded clinical AI rollouts to date.
2 | Vitalize Raises $31M Series A to Bring "Air Traffic Control" to Healthcare | Financing
Vitalize, an AI platform for health system labor and capacity management, raised a $31M Series A led by Oak HC/FT, with participation from Norwest, .406 Ventures, Constellation Ventures, Y Combinator, and the MemorialCare Innovation Fund. The platform uses machine learning, optimization models, and AI agents to forecast staffing needs and fill schedule gaps.
3 | Sentara Health Deploys New AI Case Management Tool Co-Developed with Regard | New Product
Sentara Health deployed a case management tool co-developed with clinical decision support company Regard, which lets case managers query patient charts in plain language and see changes from the previous 24 hours to inform discharge and level-of-care decisions. Regard is already used across all 12 Sentara hospitals, and the health system plans to extend the new tool beyond acute care into ambulatory settings.
.png)
